IMPACT OF ANDROGEN DEPRIVATION MODALITIES ON SURVIVAL AND QUALITY OF LIFE IN ADVANCED PROSTATE CANCER
Abstract
Resume. Androgen deprivation therapy (ADT) remains the cornerstone of treatment for advanced and metastatic prostate cancer. However, the choice of ADT modality significantly influences not only oncological outcomes but also treatment tolerability and quality of life. This study evaluates the comparative effectiveness and quality-of-life outcomes of various androgen deprivation strategies, including surgical castration, luteinizing hormone–releasing hormone (LHRH) agonists, LHRH antagonists, and combined androgen blockade. Clinical response, prostate-specific antigen (PSA) dynamics, survival outcomes, adverse events, and patient-reported quality-of-life indicators were analyzed. The results demonstrate that combined androgen blockade provides superior oncological control, while LHRH antagonists offer a favorable balance between efficacy and tolerability. These findings support an individualized approach to hormonal therapy selection in patients with advanced prostate cancer. Keywords: prostate cancer; androgen deprivation therapy; LHRH agonists; LHRH antagonists; combined androgen blockade; quality of life.